Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 55,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $15.77, for a total transaction of $867,350.00. Following the completion of the sale, the chief executive officer now directly owns 429,398 shares of the company’s stock, valued at approximately $6,771,606.46. This trade represents a 11.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $17.44, for a total transaction of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total value of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total value of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.89, for a total transaction of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $30,479.04.

Centessa Pharmaceuticals Price Performance

CNTA stock opened at $16.68 on Thursday. The company has a fifty day simple moving average of $16.80 and a two-hundred day simple moving average of $14.79. Centessa Pharmaceuticals plc has a 52 week low of $7.38 and a 52 week high of $18.97. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $2.20 billion, a P/E ratio of -10.90 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. Analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on CNTA shares. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim raised their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of CNTA. Mirae Asset Global Investments Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC boosted its stake in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP boosted its stake in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP bought a new position in Centessa Pharmaceuticals during the 2nd quarter valued at about $90,000. Finally, Fred Alger Management LLC purchased a new stake in Centessa Pharmaceuticals in the 2nd quarter worth about $99,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.